Francesco Cinetto
Overview
Explore the profile of Francesco Cinetto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ceccato J, Gualtiero G, Piazza M, Carraro S, Buso H, Felice C, et al.
Cells
. 2025 Feb;
14(4).
PMID: 39996765
In vitro models serve as valuable tools for understanding the complex cellular and molecular interactions involved in granuloma formation, providing a controlled environment to explore the underlying mechanisms of their...
2.
Pulvirenti F, Milito C, Cinetto F, Garzi G, Sardella G, Spadaro G, et al.
J Allergy Clin Immunol Glob
. 2025 Jan;
4(1):100384.
PMID: 39867744
Background: Many patients with X-linked agammaglobulinemia (XLA) nowadays have reached adulthood, as well as their sisters, possibly carriers of a deleterious Bruton tyrosine kinase variant. Studies on motherhood outcomes in...
3.
Zoletto S, Pizzi M, De Crescenzo A, Friziero A, DAmore F, Carli G, et al.
J Clin Med
. 2025 Jan;
14(1.
PMID: 39797114
: Splenectomy leads to a high rate of remission in chronic primary immune thrombocytopenia (ITP), but its unpredictable long-term positive outcomes and that it is a irreversible surgical approach discourage...
4.
Buso H, Firinu D, Gambier R, Scarpa R, Garzi G, Soccodato V, et al.
J Allergy Clin Immunol
. 2024 Nov;
155(3):1027-1035.
PMID: 39566607
Background: Respiratory disease is a frequent cause of morbidity and mortality in common variable immunodeficiencies (CVIDs); however, lung function trajectories are poorly understood. Objective: We sought to determine lung physiology...
5.
van Stigt A, Gualtiero G, Cinetto F, Dalm V, IJspeert H, Muscianisi F
Curr Opin Allergy Clin Immunol
. 2024 Oct;
24(6):479-487.
PMID: 39431514
Purpose Of Review: The pathogenesis of granulomatous disease in common variable immunodeficiency (CVID) is still largely unknown, which hampers effective treatment. This review describes the current knowledge on the pathogenesis...
6.
Buso H, Discardi C, Bez P, Muscianisi F, Ceccato J, Milito C, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062076
Sarcoidosis and Granulomatous and Lymphocytic Interstitial Lung Diseases (GLILD) are two rare entities primarily characterised by the development of Interstitial Lung Disease (ILD) in the context of systemic immune dysregulation....
7.
Miedema J, Cinetto F, Smed-Sorensen A, Spagnolo P
J Autoimmun
. 2024 May;
149:103247.
PMID: 38734536
Sarcoidosis is a granulomatous multiorgan disease, thought to result from exposure to yet unidentified antigens in genetically susceptible individuals. The exaggerated inflammatory response that leads to granuloma formation is highly...
8.
Sambugaro G, Brambilla E, Costanzo G, Bonato V, Ledda A, Del Giacco S, et al.
Life (Basel)
. 2024 Mar;
14(3).
PMID: 38541703
This is a multicentric investigation involving two Italian centers that examined the clinical course of COVID-19 in patients receiving biological therapy targeting type 2 inflammation and those not receiving biologicals....
9.
Villa A, Milito C, Deiana C, Gambier R, Punziano A, Buso H, et al.
J Clin Immunol
. 2024 Feb;
44(2):59.
PMID: 38319477
The long-term effects of SARS-CoV-2 infection represent a relevant global health problem. Long COVID (LC) is defined as a complex of signs and symptoms developed during or after SARS-CoV-2 infection...
10.
Bettiol A, Urban M, Padoan R, Groh M, Lopalco G, Egan A, et al.
Lancet Rheumatol
. 2024 Jan;
5(12):e707-e715.
PMID: 38251561
Background: Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort...